1/ You’re merging gene data across tools. Suddenly nothing matches.
ENSEMBL, ENTREZ, TP53, P53…
Why so many gene IDs?
ENSEMBL, ENTREZ, TP53, P53…
Why so many gene IDs?
July 24, 2025 at 1:45 PM
1/ You’re merging gene data across tools. Suddenly nothing matches.
ENSEMBL, ENTREZ, TP53, P53…
Why so many gene IDs?
ENSEMBL, ENTREZ, TP53, P53…
Why so many gene IDs?
🔬 Un equipo del @ciccancer.bsky.social ha identificado a la proteína Capicua como pieza crucial en la resistencia de los tumores con mutaciones en KRAS y TP53.
🧬 Una vía a terapias más personalizadas y eficaces en #CáncerDePulmón.
Más info ➡️ saladeprensa.usal.es/node/139691
🧬 Una vía a terapias más personalizadas y eficaces en #CáncerDePulmón.
Más info ➡️ saladeprensa.usal.es/node/139691
November 17, 2025 at 10:34 AM
🔬 Un equipo del @ciccancer.bsky.social ha identificado a la proteína Capicua como pieza crucial en la resistencia de los tumores con mutaciones en KRAS y TP53.
🧬 Una vía a terapias más personalizadas y eficaces en #CáncerDePulmón.
Más info ➡️ saladeprensa.usal.es/node/139691
🧬 Una vía a terapias más personalizadas y eficaces en #CáncerDePulmón.
Más info ➡️ saladeprensa.usal.es/node/139691
𝐓𝐏𝟓𝟑 is the gene that encodes the tumor-suppressor protein p53.
Full definition of this NEJM Illustrated Glossary term: nej.md/4cINZuK
#ScienceSky
Full definition of this NEJM Illustrated Glossary term: nej.md/4cINZuK
#ScienceSky
March 3, 2026 at 6:34 PM
𝐓𝐏𝟓𝟑 is the gene that encodes the tumor-suppressor protein p53.
Full definition of this NEJM Illustrated Glossary term: nej.md/4cINZuK
#ScienceSky
Full definition of this NEJM Illustrated Glossary term: nej.md/4cINZuK
#ScienceSky
#ImmunologyNews Mutations in TP53 are among the most common changes in cancer...#cancer #immunotherapy #immunology #research
Read more here: https://ow.ly/uVFC50ZPrxJ
Read more here: https://ow.ly/uVFC50ZPrxJ
September 21, 2026 at 10:00 AM
#ImmunologyNews Mutations in TP53 are among the most common changes in cancer...#cancer #immunotherapy #immunology #research
Read more here: https://ow.ly/uVFC50ZPrxJ
Read more here: https://ow.ly/uVFC50ZPrxJ
We programmed CRISPR-Cas12a2 to recognize cancer mutations, especially in TP53, and selectively kill mutant cells through transcript-activated chromatin shredding.
May 12, 2026 at 3:13 AM
We programmed CRISPR-Cas12a2 to recognize cancer mutations, especially in TP53, and selectively kill mutant cells through transcript-activated chromatin shredding.
How can we tackle TP53 mutations which are detected in ~ 52% of #NSCLC & are associated with a worse prognosis?
This study suggests that chemo agent gemcitabine could be an effective regimen for treating NSCLC patients with TP53 hotspot mutations.
www.nature.com/articles/s41... #LCSM
This study suggests that chemo agent gemcitabine could be an effective regimen for treating NSCLC patients with TP53 hotspot mutations.
www.nature.com/articles/s41... #LCSM
Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer - Cell Death Discovery
Cell Death Discovery - Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer
www.nature.com
January 29, 2025 at 9:44 AM
How can we tackle TP53 mutations which are detected in ~ 52% of #NSCLC & are associated with a worse prognosis?
This study suggests that chemo agent gemcitabine could be an effective regimen for treating NSCLC patients with TP53 hotspot mutations.
www.nature.com/articles/s41... #LCSM
This study suggests that chemo agent gemcitabine could be an effective regimen for treating NSCLC patients with TP53 hotspot mutations.
www.nature.com/articles/s41... #LCSM
Can #elephants get cancer? Despite having 100x more cells than humans, elephants get cancer far less often. Why? They have 20+ copies of a tumor-suppressing gene called TP53, plus a “zombie” gene that helps kill damaged cells before they become dangerous. globalelephants.org/...
June 6, 2025 at 8:00 PM
Can #elephants get cancer? Despite having 100x more cells than humans, elephants get cancer far less often. Why? They have 20+ copies of a tumor-suppressing gene called TP53, plus a “zombie” gene that helps kill damaged cells before they become dangerous. globalelephants.org/...
Integrated stress response activation in combination PG3 and cisplatin-treated TP53-mutated head and neck squamous carcinoma cells induces potent apoptotic response https://www.biorxiv.org/content/10.64898/2026.09.22.752907v1
September 23, 2026 at 12:45 PM
Integrated stress response activation in combination PG3 and cisplatin-treated TP53-mutated head and neck squamous carcinoma cells induces potent apoptotic response https://www.biorxiv.org/content/10.64898/2026.09.22.752907v1
Nice review.
What have we learned about TP53-mutated acute myeloid leukemia? #HemeSky
www.nature.com/articles/s41...
What have we learned about TP53-mutated acute myeloid leukemia? #HemeSky
www.nature.com/articles/s41...
What have we learned about TP53-mutated acute myeloid leukemia? - Blood Cancer Journal
Blood Cancer Journal - What have we learned about TP53-mutated acute myeloid leukemia?
www.nature.com
November 21, 2024 at 10:42 AM
Nice review.
What have we learned about TP53-mutated acute myeloid leukemia? #HemeSky
www.nature.com/articles/s41...
What have we learned about TP53-mutated acute myeloid leukemia? #HemeSky
www.nature.com/articles/s41...
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations https://www.nature.com/articles/s41588-024-02039-4 🧬🖥️🧪 https://github.com/IMTMarburg/TP53_SGE
January 7, 2025 at 7:30 PM
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations https://www.nature.com/articles/s41588-024-02039-4 🧬🖥️🧪 https://github.com/IMTMarburg/TP53_SGE
Therapy related myeloid neoplasm post CART in DLBCL arises from TP53 clones identifiable preCART… but high baseline incidence of TP53/PPM1D CH preCART.. so the challenge is identifying those with clones that will progress - Zhi Han Yeoh from @petermaccc.bsky.social. #ASH24 #hemepath #hemesky #lymsm
December 9, 2024 at 8:17 PM
Therapy related myeloid neoplasm post CART in DLBCL arises from TP53 clones identifiable preCART… but high baseline incidence of TP53/PPM1D CH preCART.. so the challenge is identifying those with clones that will progress - Zhi Han Yeoh from @petermaccc.bsky.social. #ASH24 #hemepath #hemesky #lymsm
I learned today from a DNA scientist that elephants rarely get cancer because they have 20 copies of the TP53 gene - a tumor suppressor gene. Humans have only one TP53 gene 🐘
May 29, 2025 at 1:23 AM
I learned today from a DNA scientist that elephants rarely get cancer because they have 20 copies of the TP53 gene - a tumor suppressor gene. Humans have only one TP53 gene 🐘
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis
Ogawa, Izumikawa, Tate, and colleagues show that SLFN11 induces TP53-independent apoptosis through impairment of ribosome biogenesis in response to replication stress. These findings provide insights into how SLFN11 enhances sensitivity to DNA-targeting…
dlvr.it
March 10, 2025 at 10:57 PM
SLFN11-mediated ribosome biogenesis impairment induces TP53-independent apoptosis
Cohort study #bcsm: At 15 yrs, 3/28 (8.8%) patients w/ TP53 mutation who got radiation (RT) for #breastcancer (BC) had developed an in-field #sarcoma
vs 0/420 controls with BC who got RT. No in-field sarcomas occurred w/o RT or in TP53 VUS carriers w/ RT.
ja.ma/494i44f
#OncSky #MedSky #OncoAlert
vs 0/420 controls with BC who got RT. No in-field sarcomas occurred w/o RT or in TP53 VUS carriers w/ RT.
ja.ma/494i44f
#OncSky #MedSky #OncoAlert
November 25, 2024 at 7:36 PM
Cohort study #bcsm: At 15 yrs, 3/28 (8.8%) patients w/ TP53 mutation who got radiation (RT) for #breastcancer (BC) had developed an in-field #sarcoma
vs 0/420 controls with BC who got RT. No in-field sarcomas occurred w/o RT or in TP53 VUS carriers w/ RT.
ja.ma/494i44f
#OncSky #MedSky #OncoAlert
vs 0/420 controls with BC who got RT. No in-field sarcomas occurred w/o RT or in TP53 VUS carriers w/ RT.
ja.ma/494i44f
#OncSky #MedSky #OncoAlert
Link to technical article
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Targeting cancer-specific mutations with RNA-triggered chromatin shredding - Nature
Mammalian cancer cells carrying mutations in several genes, including those encoding currently undruggable proteins, such as TP53, can be targeted selectively for cellular destruction using CRISPR–Cas...
www.nature.com
August 3, 2026 at 5:05 PM
Link to technical article
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy
has been described, but the contribution of CAR integration to oncogenesis is not
clear. Here we report a case o...
www.nejm.org
February 7, 2025 at 1:24 AM
Important report in @nejm.org from @mskcancercenter.bsky.social CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 #CARTcells #mmsm www.nejm.org/doi/full/10....
Learn more about Pu's work:
Finding the cure for therapy-related myeloid cancers: www.nature.com/articles/s41...
Engineering better TCR-T cells for treating leukemia:
pubmed.ncbi.nlm.nih.gov/40788260/
Finding the cure for therapy-related myeloid cancers: www.nature.com/articles/s41...
Engineering better TCR-T cells for treating leukemia:
pubmed.ncbi.nlm.nih.gov/40788260/
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis - Nature Genetics
Analysis of clinical trial data suggests that CDK4/6 inhibitors prevent the expansion of TP53-mutant clones in the blood, potentially mitigating the risk of secondary myeloid neoplasms in patients tre...
www.nature.com
September 22, 2026 at 4:11 PM
Learn more about Pu's work:
Finding the cure for therapy-related myeloid cancers: www.nature.com/articles/s41...
Engineering better TCR-T cells for treating leukemia:
pubmed.ncbi.nlm.nih.gov/40788260/
Finding the cure for therapy-related myeloid cancers: www.nature.com/articles/s41...
Engineering better TCR-T cells for treating leukemia:
pubmed.ncbi.nlm.nih.gov/40788260/
December 8, 2024 at 1:18 AM
Mutant p53 & therapy response - weekly report 🧬
🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy
TP53 status isn’t just biology, it’s clinical.
@biomednews.bsky.social
#p53 #CancerResearch #Oncology
biomed.news/bims-p53act/...
🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy
TP53 status isn’t just biology, it’s clinical.
@biomednews.bsky.social
#p53 #CancerResearch #Oncology
biomed.news/bims-p53act/...
bims-p53act 2026-03-29 papers
biomed.news
March 30, 2026 at 11:09 AM
Mutant p53 & therapy response - weekly report 🧬
🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy
TP53 status isn’t just biology, it’s clinical.
@biomednews.bsky.social
#p53 #CancerResearch #Oncology
biomed.news/bims-p53act/...
🔬 Highlight: TP53 mutations may predict poor response to taxane chemotherapy
TP53 status isn’t just biology, it’s clinical.
@biomednews.bsky.social
#p53 #CancerResearch #Oncology
biomed.news/bims-p53act/...
Consistent w/ PDACai (trained on gemcitabine/nab-paclitaxel outcomes) in #pancsm where TP53 LOF is a negative predictor vs to TP53 GOF and wild type subgroups. Any TP53 mutation was a negative predictor for FOLFIRINOX so it might be drug-specific in #lcsm too. #GI25 poster: linktr.ee/discotuba
January 29, 2025 at 8:59 PM
Consistent w/ PDACai (trained on gemcitabine/nab-paclitaxel outcomes) in #pancsm where TP53 LOF is a negative predictor vs to TP53 GOF and wild type subgroups. Any TP53 mutation was a negative predictor for FOLFIRINOX so it might be drug-specific in #lcsm too. #GI25 poster: linktr.ee/discotuba
As someone that's fought cancer twice, I wouldn't wish it on anyone ... Except Trump. I hope his TP53 gets mutated and he can only get treatment via publicly available insurance plans.
#dealwithit
#dealwithit
February 9, 2025 at 2:44 AM
As someone that's fought cancer twice, I wouldn't wish it on anyone ... Except Trump. I hope his TP53 gets mutated and he can only get treatment via publicly available insurance plans.
#dealwithit
#dealwithit
The 20th International TP53 Workshop is coming to Toronto!
Join global experts and dive into the latest discoveries on TP53 biology and its pivotal role in cancer therapeutics.
Registration is open! ➡️ x.com/RadMedPM/sta...
#p53Workshop #CancerResearch
Join global experts and dive into the latest discoveries on TP53 biology and its pivotal role in cancer therapeutics.
Registration is open! ➡️ x.com/RadMedPM/sta...
#p53Workshop #CancerResearch
November 19, 2025 at 3:49 PM
The 20th International TP53 Workshop is coming to Toronto!
Join global experts and dive into the latest discoveries on TP53 biology and its pivotal role in cancer therapeutics.
Registration is open! ➡️ x.com/RadMedPM/sta...
#p53Workshop #CancerResearch
Join global experts and dive into the latest discoveries on TP53 biology and its pivotal role in cancer therapeutics.
Registration is open! ➡️ x.com/RadMedPM/sta...
#p53Workshop #CancerResearch
New evidence just out shows definitive link between mechanisms driving cancer in smoking with those caused by pollution. Common mechanisms included mutations in the TP53 and EGFR genes 🧪
The mutagenic forces shaping the genomes of lung cancer in never smokers - Nature
An analysis of data from the Sherlock-Lung study provides insight into the mutational processes that contribute to lung cancer in never smokers, and looks at the possible role of factors such as ...
www.nature.com
July 3, 2025 at 7:12 AM
New evidence just out shows definitive link between mechanisms driving cancer in smoking with those caused by pollution. Common mechanisms included mutations in the TP53 and EGFR genes 🧪
3: TP53, PTEN, RAD51, KEAP1, EGFRvIII, KRAS, APOBEC
February 26, 2025 at 9:59 PM
3: TP53, PTEN, RAD51, KEAP1, EGFRvIII, KRAS, APOBEC